Related Experiment Video
Updated: Aug 5, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
[Analysis of the appropriate use of -blockers post-infarction]
E Freire Castroseiros1, J Muñiz García, A Castro Beiras
1Complexo Hospitalario de Ourense, La Coruna. efc@safo.net
Introduction:
The use of ss-blockers in patients with acute myocardial infarction has shown to improve the survival and reduce the risk of a new reinfarction.
Aim:
To quantify the use of ss-blockers in patients with acute myocardial infarction in Galicia, Spain.
Methods:
We used the database of the RIGA study (Registry of Infarctions in Galicia) including 655 consecutive patients admitted to any hospital of Galicia for acute myocardial infarction from February to July, 1995. An extensive review of the literature was previously made to establish therapeutic criteria for the use of ss-blockers in patients with acute myocardial infarction. The survey of the RIGA database was compared with the criteria established to determine the definition of appropriate usage.
Results:
210 out of 655 patients (32%) received ss-blockers. Interestingly, treatment (or lack of treatment) with ss-blockers was deemed appropriated in 51.4% of the patients. This inadequacy was related to the use of ACE inhibitors, calcium antagonists and thrombolysis.
Conclusion:
The use of ss-blockers in Galicia in patients admitted with acute myocardial infarction was markedly lower than that established by standard criteria and the use of ACE inhibitors, calcium channel blockers and thrombolysis was related to less appropriate use.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management